Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.

Frederick W ThielenAnnemieke van Dongen-LeunisAlexander M M AronsJudith R LadesteinPeter M HoogerbruggeCarin A Uyl-de Groot

Published in: European journal of haematology (2020)

At the current price and WTP threshold, tisagenlecleucel is cost-effective from both a healthcare and a societal perspective. Nevertheless, long-term effectiveness data are needed to validate the several assumptions that were necessary for this model.

Keyphrases

acute lymphoblastic leukemia
healthcare
allogeneic hematopoietic stem cell transplantation
randomized controlled trial
electronic health record
systematic review
big data
acute myeloid leukemia
multiple myeloma
nk cells
cell therapy
hodgkin lymphoma
mesenchymal stem cells
artificial intelligence
deep learning